OKYO Stock Forecast & Price Target

OKYO Pharma Ltd has made significant progress in the clinical development of its lead therapeutic candidate, urcosimod, which targets inflammatory eye diseases and chronic pain. Notably, clinical trial results indicate that 67% of patients treated with 0.05% urcosimod experienced over 50% improvement in pain, compared to only 33% in the placebo group, with reductions in pain scores observed as early as Week 4. These promising efficacy results position OKYO Pharma favorably within the biopharmaceutical market, potentially enhancing its growth prospects.

OKYO Pharma Ltd reported a net loss of $4.7 million, equivalent to $0.12 per share, for the fiscal year ending on March 31, 2025, suggesting ongoing financial challenges. The company's therapeutic candidate, urcosimod, is surrounded by significant risks, including potential failure in clinical trials, regulatory approval hurdles, and competition within a constrained market. Furthermore, the baseline condition of patients in the urcosimod trial raises concerns, as all participants had moderate to severe pain compared to the placebo group, indicating the potential for adverse outcomes affecting clinical success.